What the National COVID-19 Clinical Evidence Taskforce did in 2020

18 January 2021

The ASA is represented on the National COVID-19 Clinical Evidence Taskforce, which spent 2020 evaluating scientific evidence for clinical management for COVID-19 patients to help Australian clinicians provide the best possible care to Australian COVID-19 patients. 

In June 2020 our President Elect Sutapa Mukherjee took on the role of Co-Chair of the Guidelines Leadership Group. This group oversees all other panels made up of clinicians focused on reviewing new evidence of disease-modifying therapies and chemoprophylaxis, hospital and acute care, primary and chronic care, and critical care.  ASA President, Alan Young, has been an active member of the Taskforce National Steering Committee which also meets weekly. 

The work of the Taskforce was continually updated each week on its website, with 100% consensus needed from all panels prior to the update being released. This work is ongoing and will likely expand in 2021 with a new committee being formed to review infection prevention and control.

This handy infographic summarises the Taskforce’s work during the busy year that was 2020.